Literature DB >> 15292332

Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

Jeffrey S Cohn1, Bruce W Patterson, Kris D Uffelman, Jean Davignon, George Steiner.   

Abstract

Overweight individuals with reduced insulin sensitivity often have mild to moderate hypertriglyceridemia. To investigate the role of apolipoprotein (apo)C-III metabolism in the etiology of hypertriglyceridemia in these individuals, we investigated 10 male subjects with different body weights (body mass index, 24-34 kg/m(2)) and insulin sensitivity (homeostasis model assessment, 4.7-35.0). Total plasma and very-low-density lipoprotein (VLDL) apoC-III kinetics, as well as VLDL triglyceride (TG) and VLDL apoB kinetics, were measured with iv injected stable isotopes. The apoC-III, TG, and apoB levels in VLDL ranged from 2.9-18.2 mg/dl, 0.49-2.89 mmol/liter, and 6.7-29.3 mg/dl, respectively. Mean production rates (PRs) were: VLDL apoC-III, 20.2 +/- 4.1 micromol/d (range, 8.0-44.8); VLDL TG, 26.9 +/- 4.6 mmol/d (range, 10.2-51.1); and VLDL apoB, 4.4 +/- 0.8 micromol/d (range, 1.5-9.1). VLDL apoC-III PRs were significantly correlated with body mass index, homeostasis model assessment, and plasma TG (r = 0.66, P < 0.05; r = 0.80, P < 0.01; r = 0.95, P < 0.001, respectively). Similar correlations were found for plasma apoC-III PRs (r = 0.70, P < 0.05; r = 0.67, P < 0.05; r = 0.80, P < 0.01, respectively). Fractional catabolic rates (FCRs) were not significantly related to metabolic variables. VLDL TG levels were strongly related to VLDL apoC-III levels (r = 0.99, P < 0.001) and VLDL apoC-III PRs (r = 0.94, P < 0.001). VLDL apoC-III levels were more strongly correlated with VLDL TG PRs (r = 0.81, P < 0.01) than with VLDL TG FCRs or VLDL apoB FCRs (r = -0.53, P = 0.12; r = -0.37, P = 0.29). These results suggest that increased hepatic production of VLDL apoC-III is characteristic of subjects with higher body weights and lower levels of insulin sensitivity and is strongly related to the plasma concentration and level of production of VLDL TG.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292332     DOI: 10.1210/jc.2003-032056

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  56 in total

Review 1.  Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.

Authors:  David E Cohen; Edward A Fisher
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

2.  Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.

Authors:  Nathan L Meyers; Mikael Larsson; Evelina Vorrsjö; Gunilla Olivecrona; Donald M Small
Journal:  J Lipid Res       Date:  2017-02-03       Impact factor: 5.922

Review 3.  Role of triglyceride-rich lipoproteins in diabetic nephropathy.

Authors:  John C Rutledge; Kit F Ng; Hnin H Aung; Dennis W Wilson
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

Review 4.  Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis.

Authors:  Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Anton Stalenhoef
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-10-17       Impact factor: 4.690

5.  Is APOC3 the driver of cardiovascular disease in people with type I diabetes mellitus?

Authors:  Henry N Ginsberg; Gissette Reyes-Soffer
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

Review 6.  Lipotoxicity as a trigger factor of renal disease.

Authors:  Adriana Izquierdo-Lahuerta; Cristina Martínez-García; Gema Medina-Gómez
Journal:  J Nephrol       Date:  2016-03-08       Impact factor: 3.902

7.  Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size.

Authors:  Daniël B van Schalkwijk; Albert A de Graaf; Ben van Ommen; Kees van Bochove; Patrick C N Rensen; Louis M Havekes; Niek C A van de Pas; Huub C J Hoefsloot; Jan van der Greef; Andreas P Freidig
Journal:  J Lipid Res       Date:  2009-06-10       Impact factor: 5.922

8.  Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions.

Authors:  Meenakshi Sundaram; Shumei Zhong; Maroun Bou Khalil; Philip H Links; Yang Zhao; Jahangir Iqbal; M Mahmood Hussain; Robin J Parks; Yuwei Wang; Zemin Yao
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922

Review 9.  Genetically modified pigs to model human diseases.

Authors:  Tatiana Flisikowska; Alexander Kind; Angelika Schnieke
Journal:  J Appl Genet       Date:  2014-02       Impact factor: 3.240

10.  ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

Authors:  Anne Hiukka; Marcus Ståhlman; Camilla Pettersson; Malin Levin; Martin Adiels; Susanne Teneberg; Eeva S Leinonen; Lillemor Mattsson Hultén; Olov Wiklund; Matej Oresic; Sven-Olof Olofsson; Marja-Riitta Taskinen; Kim Ekroos; Jan Borén
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.